Pediatric oral formulation of dendrimer-N-acetyl-L-cysteine conjugates for the treatment of neuroinflammation

Venkata K. Yellepeddi, Raziye Mohammadpour, Siva Pramodh Kambhampati, Casey Sayre, Manoj K. Mishra, Kannan Rangaramanujam, Hamidreza Ghandehari

Research output: Contribution to journalArticle

Abstract

N-Acetyl-L-cysteine (NAC) commonly used as an antidote in acetaminophen poisoning has shown promise in the treatment of neurological disorders such as cerebral palsy (CP). However, NAC suffers from drawbacks such as poor oral bioavailability and suboptimal blood-brain-barrier (BBB) permeability limiting its clinical success. It was previously demonstrated that intravenous administration of dendrimer-NAC (D-NAC) conjugates have shown significant promise in the targeted treatment of neuroinflammation, in multiple preclinical models. Development of an oral formulation of D-NAC may open new administrative routes for this compound. Here, we report the gastrointestinal stability, in vitro transepithelial permeability, and in vivo oral absorption and pharmacokinetics in rats of a pediatric formulation of D-NAC containing Capmul MCM (glycerol monocaprylate) as a penetration enhancer. D-NAC was stable for 6 h in all five simulated gastrointestinal fluids with no signs of chemical degradation. The apparent permeability (Papp) of D-NAC increased 9-fold in the formulation containing Capmul. The area under the curve [AUC]0-∞ of D-NAC with Capmul increased by 47% when compared to D-NAC alone. These results indicate that an oral pediatric formulation containing D-NAC and Capmul can be an effective option for the treatment of neuroinflammation.

Original languageEnglish (US)
Pages (from-to)113-116
Number of pages4
JournalInternational Journal of Pharmaceutics
Volume545
Issue number1-2
DOIs
StatePublished - Jul 10 2018

Fingerprint

Dendrimers
Acetylcysteine
Pediatrics
Permeability
Therapeutics
Antidotes
Cerebral Palsy
Acetaminophen
Nervous System Diseases
Blood-Brain Barrier
Intravenous Administration
Glycerol
Poisoning
Biological Availability
Area Under Curve
Pharmacokinetics

Keywords

  • Neuroinflammation
  • Oral bioavailability
  • PAMAM dendrimers
  • Pediatric formulations
  • Permeability
  • Pharmacokinetics

ASJC Scopus subject areas

  • Pharmaceutical Science

Cite this

Pediatric oral formulation of dendrimer-N-acetyl-L-cysteine conjugates for the treatment of neuroinflammation. / Yellepeddi, Venkata K.; Mohammadpour, Raziye; Kambhampati, Siva Pramodh; Sayre, Casey; Mishra, Manoj K.; Rangaramanujam, Kannan; Ghandehari, Hamidreza.

In: International Journal of Pharmaceutics, Vol. 545, No. 1-2, 10.07.2018, p. 113-116.

Research output: Contribution to journalArticle

Yellepeddi, Venkata K. ; Mohammadpour, Raziye ; Kambhampati, Siva Pramodh ; Sayre, Casey ; Mishra, Manoj K. ; Rangaramanujam, Kannan ; Ghandehari, Hamidreza. / Pediatric oral formulation of dendrimer-N-acetyl-L-cysteine conjugates for the treatment of neuroinflammation. In: International Journal of Pharmaceutics. 2018 ; Vol. 545, No. 1-2. pp. 113-116.
@article{37febd70d02f46af928817d8a43a8b7b,
title = "Pediatric oral formulation of dendrimer-N-acetyl-L-cysteine conjugates for the treatment of neuroinflammation",
abstract = "N-Acetyl-L-cysteine (NAC) commonly used as an antidote in acetaminophen poisoning has shown promise in the treatment of neurological disorders such as cerebral palsy (CP). However, NAC suffers from drawbacks such as poor oral bioavailability and suboptimal blood-brain-barrier (BBB) permeability limiting its clinical success. It was previously demonstrated that intravenous administration of dendrimer-NAC (D-NAC) conjugates have shown significant promise in the targeted treatment of neuroinflammation, in multiple preclinical models. Development of an oral formulation of D-NAC may open new administrative routes for this compound. Here, we report the gastrointestinal stability, in vitro transepithelial permeability, and in vivo oral absorption and pharmacokinetics in rats of a pediatric formulation of D-NAC containing Capmul MCM (glycerol monocaprylate) as a penetration enhancer. D-NAC was stable for 6 h in all five simulated gastrointestinal fluids with no signs of chemical degradation. The apparent permeability (Papp) of D-NAC increased 9-fold in the formulation containing Capmul. The area under the curve [AUC]0-∞ of D-NAC with Capmul increased by 47{\%} when compared to D-NAC alone. These results indicate that an oral pediatric formulation containing D-NAC and Capmul can be an effective option for the treatment of neuroinflammation.",
keywords = "Neuroinflammation, Oral bioavailability, PAMAM dendrimers, Pediatric formulations, Permeability, Pharmacokinetics",
author = "Yellepeddi, {Venkata K.} and Raziye Mohammadpour and Kambhampati, {Siva Pramodh} and Casey Sayre and Mishra, {Manoj K.} and Kannan Rangaramanujam and Hamidreza Ghandehari",
year = "2018",
month = "7",
day = "10",
doi = "10.1016/j.ijpharm.2018.04.040",
language = "English (US)",
volume = "545",
pages = "113--116",
journal = "International Journal of Pharmaceutics",
issn = "0378-5173",
publisher = "Elsevier",
number = "1-2",

}

TY - JOUR

T1 - Pediatric oral formulation of dendrimer-N-acetyl-L-cysteine conjugates for the treatment of neuroinflammation

AU - Yellepeddi, Venkata K.

AU - Mohammadpour, Raziye

AU - Kambhampati, Siva Pramodh

AU - Sayre, Casey

AU - Mishra, Manoj K.

AU - Rangaramanujam, Kannan

AU - Ghandehari, Hamidreza

PY - 2018/7/10

Y1 - 2018/7/10

N2 - N-Acetyl-L-cysteine (NAC) commonly used as an antidote in acetaminophen poisoning has shown promise in the treatment of neurological disorders such as cerebral palsy (CP). However, NAC suffers from drawbacks such as poor oral bioavailability and suboptimal blood-brain-barrier (BBB) permeability limiting its clinical success. It was previously demonstrated that intravenous administration of dendrimer-NAC (D-NAC) conjugates have shown significant promise in the targeted treatment of neuroinflammation, in multiple preclinical models. Development of an oral formulation of D-NAC may open new administrative routes for this compound. Here, we report the gastrointestinal stability, in vitro transepithelial permeability, and in vivo oral absorption and pharmacokinetics in rats of a pediatric formulation of D-NAC containing Capmul MCM (glycerol monocaprylate) as a penetration enhancer. D-NAC was stable for 6 h in all five simulated gastrointestinal fluids with no signs of chemical degradation. The apparent permeability (Papp) of D-NAC increased 9-fold in the formulation containing Capmul. The area under the curve [AUC]0-∞ of D-NAC with Capmul increased by 47% when compared to D-NAC alone. These results indicate that an oral pediatric formulation containing D-NAC and Capmul can be an effective option for the treatment of neuroinflammation.

AB - N-Acetyl-L-cysteine (NAC) commonly used as an antidote in acetaminophen poisoning has shown promise in the treatment of neurological disorders such as cerebral palsy (CP). However, NAC suffers from drawbacks such as poor oral bioavailability and suboptimal blood-brain-barrier (BBB) permeability limiting its clinical success. It was previously demonstrated that intravenous administration of dendrimer-NAC (D-NAC) conjugates have shown significant promise in the targeted treatment of neuroinflammation, in multiple preclinical models. Development of an oral formulation of D-NAC may open new administrative routes for this compound. Here, we report the gastrointestinal stability, in vitro transepithelial permeability, and in vivo oral absorption and pharmacokinetics in rats of a pediatric formulation of D-NAC containing Capmul MCM (glycerol monocaprylate) as a penetration enhancer. D-NAC was stable for 6 h in all five simulated gastrointestinal fluids with no signs of chemical degradation. The apparent permeability (Papp) of D-NAC increased 9-fold in the formulation containing Capmul. The area under the curve [AUC]0-∞ of D-NAC with Capmul increased by 47% when compared to D-NAC alone. These results indicate that an oral pediatric formulation containing D-NAC and Capmul can be an effective option for the treatment of neuroinflammation.

KW - Neuroinflammation

KW - Oral bioavailability

KW - PAMAM dendrimers

KW - Pediatric formulations

KW - Permeability

KW - Pharmacokinetics

UR - http://www.scopus.com/inward/record.url?scp=85046783244&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85046783244&partnerID=8YFLogxK

U2 - 10.1016/j.ijpharm.2018.04.040

DO - 10.1016/j.ijpharm.2018.04.040

M3 - Article

VL - 545

SP - 113

EP - 116

JO - International Journal of Pharmaceutics

JF - International Journal of Pharmaceutics

SN - 0378-5173

IS - 1-2

ER -